A recent study found that topical application of a cream containing B'utyQuin supported skin elasticity, hydration, firmness, and luminosity.
A recent study1 published in SOFW Journal found that topical application of a cream containing B'utyQuin supported skin elasticity, hydration, firmness, and luminosity. B'utyQuin, manufactured by TriNutra and distributed by Barrington Nutritionals (Harrison, NY), is a standardized extract of Nigella sativa (black seed oil) that is standardized to 3% thymoquinone and very low free fatty acids. In the single-center, randomized, blinded, placebo-controlled trial, 22 health male and female subjects between the ages of 35 and 65 were given a cream with the black seed oil and a placebo cream, each of which was to be applied to one side of their face, daily for 28 days.
Results showed that application of the black seed oil cream presented an 11.2% improvement in skin firmness after 28 days, compared to 5.5% in the placebo group, which is a statistically significant difference. The cream with black seed oil also resulted in a 6.8% increase in skin elasticity, 22.2% increase in skin hydration, and a 1.1% increase in skin luminosity, all of which were statistically significant compared to results in the placebo group. In vitro research points to the ingredient’s antioxidant and anti-inflammatory activities and the promotion of mitochondrial biogenesis as the likely mechanisms of action.
"With a minimum of 3% thymoquinone and very low free fatty acid content, B'utyQuin has shown its ability to impact skin appearance positively," said Morris Zelkha, CEO of TriNutra, in a press release. "In addition, B'utyQuin was found to be safe and compatible with all skin types of the study participants. Because of its ability to address skin aging at a cellular level, B'utyQuin can help the body's natural functions to keep the skin healthy."
Reference
Kaneka Nutrients to unveil new consumer research on menopausal women at Vitafoods Europe 2024
April 26th 2024The company will reveal the results of the research that is based on live feedback from 200 menopausal women who took 200 mg per day of Kaneka Ubiquinol over two-months, monitored the effects, and recorded their observations.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.